LARGE-SCALE PROCESSING OF BIOLOGICAL MATERIAL

试点工厂(生物技术单位)结合了几种不同类型的 活动。它负责大规模生产细菌， 哺乳动物细胞和各种来源的生物活性化合物。 与此活动并行，它还进行相关的流程开发工作 有了这些准备工作，才能有效地执行它们。 此外，该股进行的研究工作不一定与 目前的项目，但工作对 单位的表现。 在过去的一年里，该股生产了185种不同的大型 制剂，包括以10至300的体积培养的微生物 升，哺乳动物细胞体积增长高达50升，并加工 各种生物材料。 对大规模提纯的两种物质进行了工艺开发工作 临床试验第一阶段所需的蛋白质。一种是改进型 重组大肠杆菌中铜绿假单胞菌外毒素A的形态及 二是来自牛视网膜的S抗原。 研究开发了一种自适应控制策略，并对其进行了仿真。 在有氧生长过程中维持溶解氧水平 微生物。

The Pilot Plant (Biotechnology Unit) combines several different types of activities. It is responsible for the large-scale production of bacteria, mammalian cells and biologically active compounds from various sources. Parallel to this activity, it conducts Process development work associated with these preparations in order to be able to execute them efficiently. In addition, the unit carries on research work not necessarily associated with a current project, but work that has long-term implications for the Unit's performance. During the last year, the Unit produced 185 different large-scale preparations, including microorganism grown in volumes from 10 to 300 liters, mammalian cell growth up to 50 liter volumes and processing of various biological materials. Process development work was done on large-scale purification of two proteins needed for the first phase of clinical trials. One is a modified form of Pseudomonas aeruginosa exotoxin A from recombinant E. coli and the second is S antigen from bovine retinas. Research was conducted on developing an adaptive control strategy for maintaining the dissolved oxygen level in the aerobic growth of microorganisms.